aTyr Pharma, Inc
aTyr Pharma is a U.S.-based biotechnology company focused on discovering and developing protein-based therapeutics derived from tRNA synthetase biology. Its pipeline includes efzofitimod for inflammatory lung disease and ATYR0101 and ATYR0750, which are being studied for fibrosis and related inflammatory conditions. The company is organized around research, clinical development, and partnering from its San Diego base, with a majority-owned subsidiary in Hong Kong.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical-stage biologic candidate developed for inflammatory lung disease, including ILD and pulmonary sarcoidosis.
Preclinical and translational anti-fibrotic program studied in lung, kidney, and other fibrotic diseases.
Protein-based therapeutic program centered on FGFR4 biology and inflammation/fibrosis pathways.
Partner-funded development rights, milestones, and potential royalties from regional licensing deals.
Customers
aTyr does not sell commercial medicines broadly; its economic counterparties are primarily pharmaceutical partners, research collaborators, and future healthcare providers that would use approved therapies. The most visible partner in the disclosures is Kyorin in Japan, which funds development and commercialization rights for efzofitimod in that market. If products are approved, customers would ultimately be hospitals, specialists, and patients in pulmonary and fibrotic disease settings.
Partners such as Kyorin that obtain regional rights and fund development, regulatory, and commercialization work.
Investigators, CROs, and trial sites that conduct studies needed to advance product candidates.
Pulmonologists and other specialists who would prescribe approved therapies for ILD or fibrosis.
End patients who would receive efzofitimod or related therapies if approved.
Strategy
aTyr’s strategy centers on advancing differentiated protein-based drug candidates through clinical development and using partnerships to extend reach into selected markets. The company also seeks to preserve optionality by combining internal development with regional licensing, which can fund trials while limiting the need to build a full commercial organization before approval. Its competitive position depends on demonstrating clinical differentiation in fibrosis and inflammatory disease and on protecting intellectual property around its platform and candidates.
Clinical proof-of-concept is the main driver of value in a pre-commercial biotech model.
Regional partners can fund development and create non-dilutive capital sources.
If approval approaches, the company needs market access, distribution, and stakeholder capabilities.
Geography
aTyr is headquartered and conducts substantially all of its activities in San Diego, California, while also consolidating a majority-owned subsidiary in Hong Kong. Its disclosed commercial geography is selective rather than broad: Japan is the key partnered market for efzofitimod through Kyorin, while the U.S. remains the core research and development base. Geography matters because the company’s value creation depends on where clinical work is run, where rights are licensed, and where future commercialization infrastructure would need to be built.
Risks
The company faces the core biotech risks of clinical failure, regulatory uncertainty, and the possibility that its candidates never reach approved commercialization. Because it has no established sales infrastructure and depends on external funding and partnerships, execution risk is concentrated in trial outcomes, capital access, and partner performance. Intellectual property protection, competition from larger drug developers, and macro/market volatility also matter because they can affect both valuation and financing capacity.
- Clinical development failureImpact: CriticalLikelihood: High
The company’s value depends on proving that efzofitimod and other candidates are safe and effective.
Exposure - Regulatory pathway uncertaintyImpact: HighLikelihood: High
Pulmonary sarcoidosis lacks an established FDA approval pathway, increasing approval risk even after positive data.
Exposure: EFZO-FIT study
- Financing and dilution riskImpact: HighLikelihood: High
The company has not generated substantial product revenue and relies on equity, partnerships, and licensing.
Exposure: ATM program and future capital raises
- Commercialization execution riskImpact: HighLikelihood: Medium
It has no sales, marketing, or distribution infrastructure and may need third parties to commercialize products.
Exposure: Future approved products
- IP and patent riskImpact: HighLikelihood: Low
Loss or narrowing of patent protection could reduce exclusivity and bargaining power.
Exposure: Product candidates and platform biology
- Competitive pressureImpact: MediumLikelihood: Medium
Large pharmaceutical and biotech companies are developing therapies in ILD and fibrosis.
Exposure: Inflammatory lung disease and fibrosis markets
Accounting
Judgemental itemsClinical and preclinical vendors invoice in arrears, so management must estimate unpaid costs each period.
Impact: Affects operating expense timing and quarterly comparability
Kyorin-related payments are recognized based on contract terms and achievement of milestones.
Impact: Affects reported revenue timing and volatility
A meaningful part of employee and consultant compensation is equity-based in a development-stage biotech.
Impact: Affects R&D and G&A expense
The company holds cash, restricted cash, and available-for-sale investments that require valuation and classification judgments.
Impact: Affects liquidity presentation and other comprehensive income
Similar listed companies
Publicly listed companies with a comparable business focus.
Gyre Therapeutics, Inc
GYRE · Pharmaceutical Preparations
Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases.
CytoDyn Inc.
CYDY · Pharmaceutical Preparations
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Azitra, Inc.
AZTR · Pharmaceutical Preparations
Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Last updated: 24/09/2026